- Home
- NUW vs FHTX Comparison
NUW vs FHTX Comparison
Compare NUW & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- FHTX
- Stock Information
- Founded
- NUW 2008
- FHTX 2015
- Country
- NUW United States
- FHTX United States
- Employees
- NUW N/A
- FHTX N/A
- Industry
- NUW Investment Managers
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- NUW Finance
- FHTX Health Care
- Exchange
- NUW Nasdaq
- FHTX Nasdaq
- Market Cap
- NUW 246.8M
- FHTX 278.1M
- IPO Year
- NUW N/A
- FHTX 2020
- Fundamental
- Price
- NUW $13.68
- FHTX $4.98
- Analyst Decision
- NUW
- FHTX Strong Buy
- Analyst Count
- NUW 0
- FHTX 8
- Target Price
- NUW N/A
- FHTX $12.63
- AVG Volume (30 Days)
- NUW 45.3K
- FHTX 106.1K
- Earning Date
- NUW 01-01-0001
- FHTX 08-05-2025
- Dividend Yield
- NUW 3.66%
- FHTX N/A
- EPS Growth
- NUW N/A
- FHTX N/A
- EPS
- NUW N/A
- FHTX N/A
- Revenue
- NUW N/A
- FHTX $24,173,000.00
- Revenue This Year
- NUW N/A
- FHTX $33.60
- Revenue Next Year
- NUW N/A
- FHTX $5.87
- P/E Ratio
- NUW N/A
- FHTX N/A
- Revenue Growth
- NUW N/A
- FHTX N/A
- 52 Week Low
- NUW $12.45
- FHTX $2.95
- 52 Week High
- NUW $14.44
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- NUW 49.35
- FHTX 44.97
- Support Level
- NUW $13.71
- FHTX $4.48
- Resistance Level
- NUW $13.85
- FHTX $5.23
- Average True Range (ATR)
- NUW 0.10
- FHTX 0.39
- MACD
- NUW 0.01
- FHTX -0.07
- Stochastic Oscillator
- NUW 35.88
- FHTX 23.65
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.